NCT05623839

A Study of LY3305677 in Participants With Obesity Or Overweight

A Multiple Dose Titration Study in Participants With Obesity or Overweight to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	LY3305677	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2022-11-16
• Primary completion: 2023-06-27
• Completion: 2023-06-27
• First posted: 2022-11-21
• Last updated: 2023-07-05

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study